Patient-reported outcomes (PROs) <65 or ≥ 65 years old (yo) from CARES-310 camrelizumab plus rivoceranib vs sorafenib as first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC)

被引：1

作者：

Chan, Stephen Lam

Kaseb, Ahmed Omar

Shi, Wei

Alexander, Laura

Meng, Xianzhang

Park, Cheolhee

Ryan, Kristin

Vogel, Arndt

机构：

[1] Chinese Univ Hong Kong, Hong Kong Canc Inst, Dept Clin Oncol, State Key Lab Translat Oncol, Hong Kong, Peoples R China

[2] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA

[3] Jiangsu Hengrui Pharmaceut, Shanghai, Peoples R China

[4] Elevar Therapeut, Ft Lee, NJ USA

[5] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期

关键词：

D O I：

10.1200/JCO.2024.42.3_suppl.456

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：456 / 456

页数：1

共 33 条

[1] Clinical outcomes of camrelizumab plus rivoceranib vs sorafenib (CARES-310) as first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC) of non-viral and viral etiology.
Shroff, Rachna T.
Shi, Wei
Wu, Xiuzhi
Meng, Xianzhang
Maj, Melissa
Ryan, Kristin
Galloway, Chris
Alexander, Laura
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
[2] Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.
Vogel, Arndt
Chan, Stephen Lam
Ren, Zhenggang
Bai, Yuxian
Gu, Shanzhi
Lin, Xiaoyan
Chen, Zhendong
Jia, Weidong
Jin, Yongdong
Guo, Yabing
Hu, Xiaohua
Sultanbaev, Alexander Valerievich
Pazgan-Simon, Monika
Pisetska, Margaryta
Nip, Tsz Keung
Zhang, Haisong
Du, Jinghua
Cheng, Ann-Lii
Kaseb, Ahmed Omar
Qin, Shukui
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Qin, Shukui
Chan, Stephen L.
Gu, Shanzhi
Bai, Yuxian
Ren, Zhenggang
Lin, Xiaoyan
Chen, Zhendong
Jia, Weidong
Jin, Yongdong
Guo, Yabing
Hu, Xiaohua
Meng, Zhiqiang
Liang, Jun
Cheng, Ying
Xiong, Jianping
Ren, Hong
Yang, Fang
Li, Wei
Chen, Yajin
Zeng, Yong
Sultanbaev, Alexander
Pazgan-Simon, Monika
Pisetska, Margaryta
Melisi, Davide
Ponomarenko, Dmitriy
Osypchuk, Yurii
Sinielnikov, Ivan
Yang, Tsai-Sheng
Liang, Xiao
Chen, Chunxia
Wang, Linna
Cheng, Ann-Lii
Kaseb, Ahmed
Vogel, Arndt
LANCET, 2023, 402 (10408): : 1133 - 1146
[4] Impact of baseline liver function on survival outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with camrelizumab plus rivoceranib vs sorafenib: A post hoc analysis of study CARES-310.
Vogel, Arndt
Cheng, Ann-Lii
Shi, Wei
Jang, Seong
Alexander, Laura
Meng, Xianzhang
Raphael, Natalia
Chan, Stephen Lam
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 509 - 509
[5] Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma
Zou, Huimin
Lai, Yunfeng
Chen, Xianwen
Ung, Carolina Oi Lam
Hu, Hao
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2025, 18
[6] Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial
Qin, S.
Chan, L. S.
Gu, S.
Bai, Y.
Ren, Z.
Lin, X.
Chen, Z.
Jia, W.
Jin, Y.
Guo, Y.
Sultanbaev, A. V.
Pazgan-Simon, M.
Pisetska, M.
Liang, X.
Chen, C.
Nie, Z.
Wang, L.
Cheng, A-L.
Kaseb, A.
Vogel, A.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1401 - S1402
[7] Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis to assess the impact of treatment with camrelizumab plus rivoceranib (cam plus rivo) on quality of life vs sorafenib (sora) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study CARES-310
Moon, A.
Raphael, N.
Chan, S. L.
Kaseb, A. O.
Jang, S. H.
Meng, X.
Cheng, A-L.
Qin, S.
Vogel, A.
ANNALS OF ONCOLOGY, 2024, 35 : S663 - S663
[8] Role of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte-ratio (PLR) in unresectable hepatocellular carcinoma (uHCC): Subgroup analysis of patients treated with camrelizumab (cam) plus rivoceranib (rivo) in the CARES-310 trial
Burgoyne, Adam
Kaseb, Ahmed Omar
Shi, Wei
Alexander, Laura
Meng, Xianzhang
Ryan, Kristin
Galloway, Chris
Neubach, Will
Vogel, Arndt
Chan, Stephen Lam
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
Galle, Peter R.
Finn, Richard S.
Qin, Shukui
Ikeda, Masafumi
Zhu, Andrew X.
Kim, Tae-You
Kudo, Masatoshi
Breder, Valeriy Vladimirovich
Merle, Philippe
Kaseb, Ahmed Omar
Li, Daneng
Mulla, Sohail
Verret, Wendy
Xu, Derek-Zhen
Hernandez, Sairy
Liu, Juan
Huang, Chen
Lim, Ho Yeong
Cheng, Ann-Lii
Ducreux, Michel
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[10] Phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC)
Cheng, A. -L.
Finn, R. S.
Qin, S.
Han, K. -H.
Ikeda, K.
Piscaglia, F.
Baron, A.
Park, J. -W.
Han, G.
Jassem, J.
Blanc, J. F.
Vogel, A.
Komov, D.
Evans, T. J.
Lopez, C.
Dutcus, C.
Ren, M.
Kraljevic, S.
Tamai, T.
Kudo, M.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 211 - 211

← 1 2 3 4 →

Patient-reported outcomes (PROs) &lt;65 or ≥ 65 years old (yo) from CARES-310 camrelizumab plus rivoceranib vs sorafenib as first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC)

Patient-reported outcomes (PROs) <65 or ≥ 65 years old (yo) from CARES-310 camrelizumab plus rivoceranib vs sorafenib as first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC)